GluR1 (Ionotropic Glutamate Receptor) Peptide Control
Background Info:
The peptide control for GluR1 is intended for the immuno-adsorption of GluR1 antiserum, catalog #24439. Pre-adsorption of GluR1 antiserum, diluted 1/4000-1/8000 according to the antibody specification sheet, with 5ug/mL GluR1 peptide immunogen following the instructions below provides complete blockage of GluR1 immunolabeling. The peptide is provided as 25ug of lyophilized rat GluR1, and approximately 0.09% sodium azide, sequence 894-907. Please read the instructions carefully.
The peptide control for nNOS (C-terminal) is intended for the immuno-adsorption of nNOS (C-terminal) antiserum, catalog number 24287. Pre-adsorption of nNOS (C-terminal) antiserum, diluted according to the antibody specification sheet, with 5 µg/ml nNOS peptide immunogen following the instructions below provides complete blockage of nNOS (C-terminal) immunolabeling. The peptide is provided as 25 µg of lyophilized human nNOS, sequence 1419-1433. Please read the instructions carefully before beginning the procedure.
The peptide control for nNOS (N-terminal) is intended for the immuno-adsorption of nNOS (N-terminal) antiserum, catalog number 24431. Pre-adsorption of nNOS (N-terminal) antiserum, diluted according to the antibody specification sheet, with 5ug/ml nNOS (N-terminal) peptide immunogen following the instructions below provides complete blockage of nNOS (N-terminal) immunolabeling. The peptide is provided as 25ug of lyophilized human nNOS (N-terminal), and approximately 0.09% sodium azide, sequence 134-148. Please read the instructions carefully.
The peptide control for C-FOS is intended for the immuno-adsorption of C-FOS antiserum, catalog number 26209. Pre-adsorption of C-FOS antiserum, diluted according to the antibody specification sheet, with 5ug/ml C-FOS peptide immunogen following the instructions below provides complete blockage of C-FOS immunolabeling. The peptide is provided as 25ug of lyophilized human C-FOS, and approximately 0.09% sodium azide, sequence 4-17. Please read the instructions carefully.
The ImmunoStar peptide control for 5-HT2A Receptor is intended for the immuno-adsorption of 5-HT2A Receptor antiserum, catalog number 24288. Pre-adsorption of 5-HT2A Receptor antiserum, diluted according to the antibody specification sheet, with 5 µg/ml 5-HT2A Receptor peptide immunogen following the instructions below provides complete blockage of 5-HT2A Receptor immunolabeling. The peptide is provided as 25 µg of lyophilized rat 5-HT2A Receptor, sequence 22-41. Also, this antiserum contains 0.09% sodium azide. Please read the instructions carefully before beginning the procedure.
The peptide control for 5-HT Transporter is intended for the immuno-adsorption of 5-HT Transporter antiserum, catalog number 24330. Pre-adsorption of 5-HT Transporter antiserum, diluted according to the antibody specification sheet, with 5 µg/ml 5-HT Transporter peptide immunogen following the instructions below provides complete blockage of 5-HT Transporter immunolabeling. The peptide is provided as 25 µg of lyophilized rat 5-HT Transporter, sequence 602-622. Please read the instructions carefully before beginning the procedure.
The 5-HT Transporter Peptide Control: rat 5-HT Transporter, sequence 579-599. Pre-adsorption of 5-HT Transporter antiserum, diluted according to the antibody specification sheet, with 5 µg/ml 5-HT Transporter peptide immunogen following the instructions below provides complete blockage of 5-HT Transporter immunolabeling. The peptide is provided as 25 µg of lyophilized rat 5-HT Transporter, sequence 602-622.
Pre-adsorption of Mu Opioid Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/ml Mu Opioid Receptor peptide immunogen following the instructions below provides complete blockage of Mu Opioid Receptor immunolabeling.
The peptide control for Neurokinin 1 Receptor is intended for the immuno-adsorption of Neurokinin 1 Receptor antiserum, catalog number 20060. Pre-adsorption of Neurokinin 1 Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/mL NK1R peptide immunogen following the instructions below provides complete blockage of Neurokinin 1 Receptor immunolabeling.
The peptide control for Neurokinin 1 Receptor is intended for the immuno-adsorption of Neurokinin 1 Receptor antiserum, catalog number 20060. Pre-adsorption of Neurokinin 1 Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/mL NK1R peptide immunogen following the instructions below provides complete blockage of Neurokinin 1 Receptor immunolabeling. The peptide is provided as 100 µL of 50 mg of synthetic peptide corresponding to rat NK1R 393-407.
The gamma amino butyric acid antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat thalamus and cerebellum using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/15,000- 1/20,000 in PBS /0.3% Triton X-100 - biotin/avidin-HRP technique. The specificity of the antiserum for GABA was evaluated using a competitive inhibition ELISA. While conjugates of GABA completely eliminate labeling, a 1000 fold excess of the following conjugates could not inhibit the antiserums ability to bind GABA conjugate: glutamate, aspartate, beta alanine, tyrosine, taurine, glycine and alanine.
The 5-HT BSA/Conjugate Control was prepared by cross-linking 5-HT creatinine sulfate complex to BSA with paraformaldehyde. Pre-adsorption of Serotonin antisera, diluted according to the antibody specification sheet, with 20 µg/ml Serotonin/BSA conjugate following the instructions below provides complete blockage of Serotonin immunolabeling. The conjugate is provided as 50 µg of lyophilized Serotonin creatinine sulfate coupled to BSA with paraformaldehyde.
This antibody has been shown to react strongly with human GFAP as well as with GFAP from rat, mouse, guinea pig, hamster, kangaroo, sheep, cat and monkey. Excellent staining results were obtained when rabbit anti-glial fibrillary acidic protein serum was tested.
The GHRF (Growth Hormone Releasing Factor) Antibody was raised to rat hypothalamic GHRF (1-43). The antibody produces strong labeling of GHRH at dilutions of 1/200-1/400 using indirect immunofluorescence and at dilutions of 1/2,000 - 1/4,000 using biotin/streptavidin HRP in rat hypothalamus (median eminence). Cross reactivity of GHRF antiserum was examined using the paper spot technique of Larsson (1981). Using 2 µL, 100 pmole amounts, the following substances did not react with rat GHRF antisera diluted 1/500 using the PAP labeling method: glucagon, gastric inhibitory peptide, secretin, vasoactive intestinal peptide, peptide histidine isoleucine, pancreatic polypeptide (human or rat), human GHRF, somatostatin, insulin, ACTH, motilin, cholecystokinin octapeptide, substance P, molluscan cardioexcitatiory peptide, gastrin 34, and serotonin. GHRF antiserum had a very good reactivity using rat GHRF at 2 µL, 100 pmole amounts.
The ACTH Antibody was raised to ACTH (1-39) purified from porcine pituitary. The antibody produces a maximum fluorescein staining at a 1/100 - 1/200 dilution and a 4+ biotin-streptavidin/HRP staining at a 1/500 - 1/1000 dilution in rat anterior/intermediate pituitary. Optimal dilution will vary depending upon fixation, labeling technique and/or detection system; therefore, a dilution series is recommended. The recommened dilution series are 1/100-1/200 in PBS/0.3% Triton X-100 - FITC Technique and 1/500-1/1000 in PBS/0.3% Triton X-100 - Bn-SA/HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 100 µg/mL of ACTH.
The Insulin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat pancreatic beta cells using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions for these methods are 1/500-1/1000 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/3000-1/5000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. Immuostaining is completely abolished by soluble pre-adsorption with bovine insulin at 10 µg per mL of diluted antiserum.
The CRF Antibody was raised to synthetic ovine CRF. The ImmunoStar serotonin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat median eminence using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200 - 1/400 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/1000 - 1/2000 in PBS/0.3% Triton X-100 - Biotin/Avidin-HRP Technique. Immuno-labeling is completely abolished by preadsorption with synthetic CRF at 100 ug per mL of diluted antibody.
The Glucagon Antibody was raised to glucagon coupled to bovine thyroglobulin with glutaraldehyde. The antibody has a proven strong Biotin-Streptavidin/HRP immunostaining at a 1/500-1/1000 dilution in human pancreatic islets. Staining is completely eliminated by pretreatment of the diluted antibody in an excess of glucagon. Preadsorption of the diluted antibody with an excess of the following substances had no effect on glucagon labeling: secretin, vasoactive intestinal peptide, peptide histidine isoleucine-27, gastric inhibitory polypeptide, rat and human growth hormone releasing hormone and somatostatin.
The Beta-Endorphin Antibody was raised to synthetic human beta endorphin coupled to KLH with carbodiimide. The antibody produces a strong indirect immunofluorescent staining at a 1/200 - 1/400 dilution and a 4+ biotin-streptavidin/HRP staining at a 1/1000 - 1/2000 dilution in rat anterior pituitary. Staining is completely eliminated by pretreatment of the diluted antibody with 10-6 M of Ã-Endorphin. Pre-adsorption of the diluted antibody with 10-6M of the following substances had no effect on -Endorphin labeling: methionine enkephalin, leucine enkaphalin, dynorphin A, dynorphin B, gamma-endorphin, alpha-endorphin, ACTH and alpha-melanocyte stimulating hormone.
The antibody produces a strong postive labeling of LHRH at dilutions of 1/200-1/400 using indirect immunofluorescence and at dilutions of 1/2,000 - 1,4,000 using biotin-streptavidin/HRP in rat hypothalamus (median eminence). Optimal dilution will vary depending upon fixation, labeling technique and/or detection system; therefore, a dilution series is recommended. Staining is completely eliminated by pretreatment of the diluted antibody with 5 µg of LHRH per mL of diluted antiserum.
The Alpha-MSH Antibody was raised to synthetic human a-MSH coupled to bovine thyroglobulin with glutaraldehyde. The ImmunoStar alpha melanocyte stimulating hormone antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat pituitary using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/100-1/200 in PBS/0.3% Triton X-100 - FITC Technique and 1/4000-1/6000 in PBS/0.3% Triton X-100 - Bn/Av-HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 100 ug/mL of alpha-MSH.
The 5-HT Antibody was raised in rabbit against 5-HTP coupled to BSA with paraformaldehyde. The antibody has a proven maximum biotin-streptavidin/HRP staining at a 1/1000 - 1/2000 dilution in rat raphe nuclei. Optimal dilution will vary depending upon fixation, labeling technique and/or detection system; therefore, a dilution series is recommended. The specificity of the antiserum was evaluated using a model system of gelatin-indole plugs by a method similar to published procedures (Shipper and Tilders, 1983). Results showed that the 5-HTP antibody dose dependently stained 5-HTP but did not stain any concentration of 5-HT or 5-HIAA. The antiserum was also tested by pre-adsorption with indole/paraformaldehyde/BSA conjugates. Staining was completely blocked by pre-adsorption with 5-HTP conjugate and unaffected by 5-HIAA or 5-HT conjugate.
The 5-HIAA antibody was raised to 5-HIAA coupled to BSA with paraformaldehyde. The antibody produces moderate labeling of raphe neurons in normal rat. In rats whose serotonergic system has been activated, staining intensity is increased to a maximum label. Recommended dilutions of the antiserum are 1/200-1/400 for indirect immunofluorescence and 1/4000-1/8000 for biotin-streptavidin/HRP technique. The specificity of the antiserum was evaluated using a model system of gelatin-indole plugs by a method similar to published procedures (Schipper and Tilders, 1983). Results showed that the 5-HIAA antibody dose dependently stained 5-HIAA but did not stain any concentration of 5-HT or 5-HTP. The antiserum was also tested by pre-adsorption at 25 µg/mL with various BSA conjugates. While pre-adsorption with 5-HIAA conjugate completely eliminates immunolabeling, pre-adsorption with conjugates of 5-HT,5-HTP and dopamine had no effect on staining intensity or distribution of stain.
The antibody has a proven strong indirect immunofluorescent staining at a 1/400 - 1/600 dilution and a proven strong biotin-streptavidin/HRP staining at a 1/1000 - 1/2000 dilution in rat globus pallidus and spinal cord. Staining is completely eliminated by pretreatment with 50 µg of Leucine Enkephalin per mL of diluted antiserum. Pretreatment with 50 µg of Methionine Enkephalin per mL of diluted antiserum also significantly blocks staining.
The antibody has a proven strong indirect immunofluorescent staining at a 1/400-1/600 dilution and a proven 4+ biotin-streptavidin/HRP staining at 1/1,000-1/1,200 dilution in rat globus pallidus and amygdala. Staining is completely eliminated by pretreatment with 100 µg of methionine enkephalin per mL of diluted antiserum. Pretreatment with 100 µg of leucine enkephalin only partially blocks staining.
The Neurotensin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat amygdala using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200-1/400 in PBS/0.3% Triton x-100 - Cy3 Technique and 1/4000-1/8000 in PBS/0.3% Triton x-100 - Bn/Av-HRP Technique. Staining is completely eliminated by pretreatment with 10 µg of Neurotensin per 1 mL of diluted antibody.
Raised against a C-terminal synthetic peptide sequence corresponding to amino acids 894-907 of rat GluR1 coupled to bovine thyroglobulin with gluraraldehyde.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Rabbit
Immunogen:
Rat GluR1 (894-907)
Applications:
Immunohistochemistry, Immunocytochemistry, Western Blot
The GluR1 (lonotropic Glutamate Receptor1) Antibody was raised against a C-terminal synthetic peptide sequence corresponding to amino acids 894-907 of rat GluR1 coupled to bovine thyroglobulin with gluraraldehyde. The antibody produces strong labeling of GluR1 at dilutions of 1/4,000 - 1/6,000 using biotin-streptavidin peroxidase technique in rat cortex and hippocampus. Western blot analysis of GluR1 transfected cells and rat brain homogenates the antibody specifically labels a single band at Uapproximately 102 kD. Western blot analysis of GluR2, 3, 4, 4C, 5, 6, and 7 transfected cells revealed no immunolabeling. Immunolabeling of the above non-NMDA transfected cells demonstrates specificity for GluR1. Additionally, immunolabeling for GluR1 is completely abolished by pre-adsorption with synthetic rat GluR1 (894-907) at 5 µg per mL of diluted antibody.
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
